ReviewFrontiers in psychiatry2023
Late-life depression: Epidemiology, phenotype, pathogenesis and treatment before and during the COVID-19 pandemic.
Review in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Depression and Anxiety in Voluntarily Unemployed People: A Systematic Review.La Medicina del lavoro · 2024Pooled it
- The risk associated with ultra-processed food intake on depressive symptoms and mental health in older adults: a target trial emulation.BMC medicine · 2025Trial
- Pupillary Light Reflex and Eye Movement Parameters as Objective Measures of Cognitive Decline in Older Adults: A Secondary Analysis of a Multimodal Public Dataset.Diagnostics (Basel, Switzerland) · 2026Article
- Comprehensive analysis of interactions between brain aging and late-onset psychoses using heuristic mapping models.Communications medicine · 2026Article
- Late-Onset Depression in an Aging World: A Multidimensional Perspective on Risks, Mechanisms, and Treatment.Geriatrics (Basel, Switzerland) · 2026Review
- Psychotherapy for older adults with depression: a narrative review.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- AI-enabled multimodal neuroimaging for neurotransmitter mapping in normal aging and age-related disease.Frontiers in aging neuroscience · 2026Review
- Psychedelic interventions for major depressive disorder in the elderly: Exploring novel therapies, promise and potential.Dialogues in clinical neuroscience · 2025Review
- Association Between Unmet Healthcare Needs and Depression in Older Adults: Evidence from the Korean National Health and Nutrition Examination Survey.Healthcare (Basel, Switzerland) · 2025Article
- Ginkgo biloba L. leaf extract (EGb 761) alleviates reserpine-induced depression-like symptoms in aged rats by enhancing serotonin/norepinephrine levels and reducing oxidative/nitrosative stress.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The mediating role of instrumental activities of daily living between cognitive function and depressive symptoms in community-dwelling older adults: the Arao study.BMC psychiatry · 2025Article
- Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report.The Journal of international medical research · 2025Article
- Global, regional, and national burden of geriatric depressive disorders in people aged 60 years and older: an analysis of the Global Burden of Disease Study 2021.Annals of general psychiatry · 2025Article
- The mediating effects of sleep quality in the relationship between loneliness and depression among middle-aged and older adults.Scientific reports · 2025Article
- Mental health status and quality of life among Thai people after the COVID-19 outbreak: a cross-sectional study.Scientific reports · 2024Article
- Choice intention for the national volume-based procurement drug and its associated factors: a cross-sectional study on patients with late-life depression in China.BMC psychiatry · 2024Article
- Association between Dietary Antioxidant Capacity in Midlife and Depressive Symptoms in Late Life: The Singapore Chinese Health Study.Antioxidants (Basel, Switzerland) · 2024Article
- The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late-life depression (LLD) is one of the most common mental disorders among the older adults. Population aging, social stress, and the COVID-19 pandemic have significantly affected the emotional health of older adults, resulting in a worldwide prevalence of LLD. The clinical phenotypes between LLD and adult depression differ in terms of symptoms, comorbid physical diseases, and coexisting cognitive impairments. Many pathological factors such as the imbalance of neurotransmitters, a decrease in neurotrophic factors, an increase in β-amyloid production, dysregulation of the hypothalamic-pituitary-adrenal axis, and changes in the gut microbiota, are allegedly associated with the onset of LLD. However, the exact pathogenic mechanism underlying LLD remains unclear. Traditional selective serotonin reuptake inhibitor therapy results in poor responsiveness and side effects during LLD treatment. Neuromodulation therapies and complementary and integrative therapies have been proven safe and effective for the treatment of LLD. Importantly, during the COVID-19 pandemic, modern digital health intervention technologies, including socially assistive robots and app-based interventions, have proven to be advantageous in providing personal services to patients with LLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.